Top Canonical Pathways | p-value | Overlap | Ratio |
Super-pathway of Cholesterol Biosynthesis | 1.00E-12 | 73.9% | 17/23 |
Cholesterol Biosynthesis I-III | 1.29E-08 | 90.0% | 9/10 |
LXR/RXR Activation | 1.24E-07 | 33.3% | 24/72 |
FXR/RXR Activation | 1.14E-07 | 31.6% | 25/79 |
Triacylglycerol Biosynthesis | 1.29E-06 | 43.8% | 14/32 |
Top Upstream Regulators | p-value of overlap | # Target genes | |
PPARA | 1.00E-26 | 94 | |
SREBF1 | 5.15E-17 | 51 | |
TP53 | 8.71E-16 | 186 | |
SREBF2 | 2.88E-14 | 28 | |
FOXO1 | 4.25E-12 | 74 | |
Top Molecular and Cellular Functions | p-value | # Genes | |
Amino Acid Metabolism | 1.97E-03 - 6.58E-14 | 72 | |
Small Molecule Biochemistry | 1.97E-03 - 6.58E-14 | 358 | |
Lipid Metabolism | 1.97E-03 - 2.36E-13 | 284 | |
Molecular Transport | 1.82E-03 - 2.36E-13 | 231 | |
Vitamin and Mineral Metabolism | 1.13E-03 - 3.43E-12 | 88 | |
Physiological System Development and Function | p-value | # Genes | |
Tissue Morphology | 1.50E-03 - 1.28E-06 | 186 | |
Organismal Development | 1.87E-03 - 1.63E-06 | 373 | |
Organ Morphology | 1.16E-03 - 4.30E-06 | 123 | |
Renal and Urological System Development and Function | 1.13E-03 - 4.30E-06 | 66 | |
Embryonic Development | 1.87E-03 - 1.19E-05 | 195 | |
Toxicity Functions | p-value | # Genes | Ratio |
LXR/RXR Activation | 1.67E-07 | 32.9% | 24/73 |
FXR/RXR Activation | 2.14E-07 | 31.6% | 25/79 |
Cholesterol Biosynthesis | 2.69E-07 | 66.7% | 10/15 |
LPS/IL-1 Mediated Inhibition of RXR Function | 2.95E-05 | 22.1% | 32/145 |
Liver Necrosis/Cell Death | 5.92E-05 | 19.3% | 42/218 |
Top Up-regulated genes | log2 Ratio (E/H) | Top Down-regulated genes | log2 Ratio (E/H) |
MOGAT1 | 5.44 | THRSPA | −7.15 |
DIO3 | 5.01 | SLCO1A2 | −5.82 |
PPM1K | 4.65 | ELOVL5 | −5.60 |
PDK4 | 3.95 | CDO1 | −5.23 |
SLC13A3 | 3.82 | FASN | −5.08 |
ITGBL1 | 3.66 | SQLE | −4.92 |
TTLL2 | 3.64 | DIO2 | −4.84 |
ALKAL2 | 3.18 | NSDHL | − 4.74 |
RET | 3.16 | CYP7A1 | −4.73 |
ASCL1 | 3.11 | AFMID | −4.44 |